Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2023 · 10-Q
Revenue$5.19M$5.19M+15.5% vs Q2 2022 Net Income-$5.61M-$5.61MN/M vs Q2 2022 EPS Diluted-$0.13-$0.13N/M vs Q2 2022 Gross Profit$1,777,083+31.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,418,264N/M Free Cash Flowderived-$2,420,306N/M Margins · derivedGross margin34.2%+4.2 pt vs Q2 2022
Operating margin-81.3%+48.3 pt vs Q2 2022
Net margin-108.0%+20.0 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end